论文部分内容阅读
目的:比较每日1次甘精胰岛素联合阿卡波糖治疗老年2型糖尿病的血糖控制与安全性。方法:60例口服降糖药两种而血糖控制不理想2型糖尿病患者,年龄≥60岁,病程≥5年,随机分为A组每日1次甘精胰岛素联合阿卡波糖和B组诺和灵30R进行治疗,比较治疗后两组血糖达标时间、低血糖事件发生率、空腹血糖达标时每日所用甘精胰岛素和诺和灵30R的剂量、空腹血糖(FBG)、餐后血糖(PBG2H)、糖化血红蛋白(HbA1c)、体重指数(BMI)。结果:A组甘精胰岛素组在空腹血糖达标时间、低血糖发生率、每日胰岛素的剂量方面均低于诺和灵30R组,差异有统计学意义(P<0.01).糖化血红蛋白、两组治疗后差异无统计学意义(P>0.05).结论:每日1次甘精胰岛素注射联合口服药的血糖控制及安全达标率明显优于预混胰岛素,且患者依从性好,更易于长期坚持治疗。
OBJECTIVE: To compare the glycemic control and safety of glargine plus acarbose once daily for the treatment of type 2 diabetes in the elderly. Methods: Sixty patients with two kinds of oral hypoglycemic agents who did not control their type 2 diabetes mellitus with poor glycemic control were ≥60 years old and their duration of disease was more than 5 years. They were randomly divided into group A, insulin glargine plus acarbose and group B Novo Spirit 30R treatment, the treatment of two groups after treatment of blood glucose compliance time, incidence of hypoglycaemia, fasting blood glucose reached the standard daily glargine and Novolin 30R dose, fasting blood glucose (FBG), postprandial blood glucose (FBG) PBG2H), HbA1c, and body mass index (BMI). Results: Glargine group A was lower than norpril 30R group in the fasting blood glucose time, the incidence of hypoglycemia, the daily insulin dosage, the difference was statistically significant (P <0.01) After treatment, the difference was not statistically significant (P> 0.05) .Conclusion: Once a day insulin glargine injection oral administration of blood glucose control and safety compliance rate was significantly better than premixed insulin, and patients with good compliance, easier to long-term adherence treatment.